Eli Lilly, Novo Nordisk race to lock in India obesity drug market We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Obesity drugs are rapidly moving from the margins of lifestyle care to the centre of India’s pharmaceutical growth story as rising lifestyle diseases, new blockbuster launches and the looming entry of low-cost generics reshape the market. With global consultants McKinsey ranking obesity therapies alongside AI, electric vehicles and robotics as trillion-dollar opportunities by 2040, India…
Indian Pharma Market Posts 9% Surge in November Even as Volumes Stay Flat: PharmaTrac We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
USFDA issues EIR for Zydus Jarod injectable facility We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Mumbai: Indian drugmaker Lupin and a clutch of private equity investors including EQT Partners and TPG Capital are in separate early-stage discussions to acquire UK’s largest nutraceutical company, Vitabiotics, people aware of the development said. The potential deal is expected to value the Lalvani family-owned business at around £1 billion (`11,800 crore). Lupin is in…
Indian generic drugmakers are recalibrating their pricing strategy after Danish drugmaker Novo Nordisk decided to cut by nearly 40% prices of its weight-loss injectable semaglutide, sold under brand name Wegovy. Companies preparing for the first wave of semaglutide launches are now said to be working with a ₹3,000-5,000 band as against a ₹7,000-8,000 a month…
New Delhi, Zydus Lifesciences Ltd on Wednesday said it has entered into an exclusive licensing and commercialisation agreement with RK Pharma Inc of the US for a new sterile injectable oncology supportive care product for the US market. Under the terms of this agreement, RK Pharma will manufacture and supply the finished product, while Zydus…
Domestic drugmakers Glenmark, Granules India, Sun Pharma, Zydus and Unichem are recalling products in the US market for various manufacturing issues, according to the US Food and Drug Administration (USFDA). The drugmakers are voluntarily recalling affected lots in the American market, the US health regulator said in its latest Enforcement Report. A US-based subsidiary of…
Zydus gets USFDA EIR for Ahmedabad oncology injectable manufacturing facility We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link